AffaMed Therapeutics

Executive Summary

AffaMed Therapeutics is a Shanghai-based specialty biopharmaceutical company focused on developing and commercializing innovative therapies for ophthalmology, neuroscience, and rare diseases. Founded in 2019, the company employs 200–500 staff and operates primarily through in-licensing and co-development of late-stage assets for the Greater China and Asian markets. Its portfolio includes both small molecules and biologics targeting high-need conditions. While still private and pre-revenue, AffaMed has advanced multiple candidates to phase 3, positioning itself for near-term value inflection. The company's strategy of leveraging established science and regional expertise reduces development risk, though execution and regulatory hurdles in China remain considerations. With a lean team and focused pipeline, AffaMed represents a speculative but potentially high-reward opportunity in Asian biotech.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 Topline Data for Lead Ophthalmology Asset70% success
• Q4 2026NDA Submission for Neuroscience Candidate in China60% success
• Q3 2026New In-Licensing Deal for Rare Disease Asset50% success